



Investor Presentation

Q2 2023 Earnings Call

Curt R. Hartman

Chair of the Board, President, and Chief Executive Officer

Todd W. Garner

Executive Vice President and Chief Financial Officer

July 26, 2023

Forward-Looking Information

This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2022, listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Management has disclosed adjusted financial measurements in this presentation that present financial information that is not in accordance with generally accepted accounting principles in the United States (GAAP). The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends. These measurements are not a substitute for GAAP measurements. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated statements of income.

CONMED Vision

Empower healthcare providers worldwide to deliver exceptional outcomes for patients.

Focus behind the Vision
People, Products, Profitability



WE DO
things the
right way.




WE MAKE
and keep
commitments.



WE OPERATE
with urgency.



WE BELIEVE
in the power of
engaged talent.




WE DELIVER
exceptional results.

Objectives for Our Shareholders

- Aggregate growth and profitability over the long term to significantly increase the valuation of the company
- Evolve product mix toward higher-growth, higher-margin offerings
- Increase our market share in large and attractive markets
- Deliver above-market revenue and profitability growth over the long term

Orthopedics: Large, Attractive Markets

June 2023 YTD




76%

Recurring,
single-use revenue

Category	Description	Market Size and Competitors	Dollar Value of 1 Market Share Point
Sports Medicine & Biologics	Comprehensive portfolio of devices for repair and healing of soft tissue injuries, including implants, biologics, allograft tissue, enabling devices and related instruments	\$4.8 to \$5.0 Billion <ul style="list-style-type: none"> Arthrex DePuy Mitek (J&J) Smith & Nephew Stryker Zimmer Biomet Allosource LifeNet RTI 	~\$49M
Capital Equipment	Surgical drills/saws, high-definition surgical visualization systems, and related single-use accessories	\$3.2 to \$3.6 Billion <ul style="list-style-type: none"> Stryker DePuy Synthes (J&J) Zimmer Biomet Smith & Nephew Arthrex Olympus Richard Wolf Karl Storz Medtronic (Midas Rex/ Xomed) 	~\$34M
Foot & Ankle	Comprehensive portfolio includes implants, fracture systems, biologics, and related hardware	\$4.4 to \$4.6 Billion <ul style="list-style-type: none"> Stryker DePuy Synthes (J&J) Arthrex Paragon 28 Treace 	~\$45M
<u>Total Orthopedics</u>	60% to 70% in Surgery Centers in the U.S.		~\$128M ~12% growth for total company

General Surgery: Large, Attractive Markets

June 2023 YTD




90%


**Recurring,
single-use revenue**

Category	Description	Market Size and Competitors	Dollar Value of 1 Market Share Point
Access	A platform of devices and accessories to create and enter the surgical working space in minimally invasive procedures	\$1.4 to \$1.6 Billion <ul style="list-style-type: none"> Ethicon (J&J) Applied Medical Stryker Medtronic Olympus Karl Storz 	~\$15M
Energy	RF energy to affect tissue by cutting, sealing, or causing hemostasis in open or minimally invasive procedures. Smoke evacuation and filtration to support the surgical environment	\$2.7 to \$2.9 Billion <ul style="list-style-type: none"> Medtronic Ethicon (J&J) Olympus Stryker Cooper Surgical ERBE 	~\$28M
Instruments	Instruments and accessories for minimally invasive laparoscopic, open, and robotic approaches	\$1.5 to \$1.7 Billion <ul style="list-style-type: none"> Karl Storz Aesculap Stryker 	~\$16M
Endoscopic Technologies	Therapeutic and diagnostic endoscopic products used by Gastroenterologists	\$3.0 to \$3.2 Billion <ul style="list-style-type: none"> Boston Scientific Cook Medical Cantel Olympus Merit Endotek STERIS 	~\$31M
Critical Care	Single-use devices for monitoring cardiac activity and other patient care devices	\$0.8 to \$1.0 Billion <ul style="list-style-type: none"> 3M Company Cardinal 	~\$9M
Total General Surgery	90% to 95% in Hospitals		~\$99M ~10% growth for total company


Q2 2023 Financial Performance



Worldwide CC Revenue Growth %*



CC Revenue Growth %*




Worldwide CC Revenue Growth %*



	GAAP	Non-GAAP**
EPS	\$0.43	\$0.83
Y/Y %	N/A	9.2%

- Revenue: \$317.7M, an increase of 14.6% year over year as reported and 16.6% in constant currency. Organic constant currency revenue growth of 12.6%
- GAAP EPS: Diluted net earnings per share of \$0.43, compared to a net loss per share of \$5.65 in the prior year period
- Adjusted EPS** : Diluted net earnings per share of \$0.83, an increase of 9.2% from the prior year period

June 2023 YTD Financial Performance




Worldwide CC Revenue Growth %*

Total CNMD **20.6%**

General Surgery **18.9%**


Orthopedic Surgery **22.7%**



CC Revenue Growth %*

Domestic **21.0%**

International **20.1%**



Worldwide CC Revenue Growth %*

Single-Use **21.6%**

Capital **15.6%**

	GAAP	Non-GAAP**
EPS	\$0.49	\$1.49
Y/Y %	N/A	2.8%

- Revenue: \$613.1M, an increase of 18.0% year over year as reported and 20.6% in constant currency. Organic constant currency revenue growth of 15.8%
- GAAP EPS: Diluted net earnings per share of \$0.49, compared to a net loss per share of \$5.18 in the prior year period
- Adjusted EPS*: Diluted net earnings per share of \$1.49, an increase of 2.8% from the prior year period

Updated Full-Year 2023 Financial Guidance

	Original	Q1 Update	Current
Revenue	\$1.170 B to \$1.220 B	\$1.205 B to \$1.250 B	\$1.230 B to \$1.260 B
Adjusted Cash EPS	\$3.20 to \$3.45	\$3.30 to \$3.50	\$3.40 to \$3.55

- The expected impact of foreign currency exchange rates remains unchanged from our original guidance

Environmental, Social and Governance

Together We Are Making A Difference for a Better Tomorrow

Environmental



Chihuahua, Mexico plant has held the Clean Industry Certification since 2015



Utica, New York plant is ISO 14001 certified



100% LED lighting at Utica and Chihuahua plants

Social



Partners with United Way and TEAMFund to serve communities where we operate and provide medical innovation to underrepresented communities, respectively



98% of employees participated in the Gallup Q12 Employee Engagement Survey



Women make up 53% of our global workforce

Governance



33% gender diversity on Board of Directors



Committee Chair rotation every five years. Board Service tenure limited to 12 years



100% Independent Standing Board Committee

Closing Thoughts

- Intense focus on solving unmet needs for healthcare customers drives increased market share
- Large and attractive markets provide CONMED with ample opportunities for above-average revenue and profitability growth
- Portfolio continues to evolve toward higher-growth, higher-margin offerings
- At CONMED, we are focused on doing things the right way and being good corporate citizens





AirSeal[®] Supplemental Information

AirSeal[®] Current IP Position

	U.S.	International
Patents Issued	62	125
Patents Pending	28	96

- Current key patents extend through 2032 to 2039


AirSeal[®] Access Ports



AirSeal[®] iFS



AirSeal[®] Filtered Tube Sets



AirSeal[®]

Intelligent Flow System

THE ONLY INSUFFLATOR THAT IS BACKED BY CLINICAL DATA.*



GLOBAL IMPACT

6M

PROCEDURES

3,500

FACILITIES

72

COUNTRIES



IMPROVED PATIENT OUTCOMES

33

PEER-REVIEWED
STUDIES

6,050

PATIENTS

5

SPECIALTIES

These studies proved that operating with AirSeal:



REDUCES TIME^{1,2}

Reduces PACU time
and length of stay
Reduces procedural and
anesthesia time.



IMPROVES PULMONARY VENTILATION

Reduces etCO₂ ³⁻⁸
Reduces airway pressure ^{2,3,5-8}
Increases pulmonary compliance ⁵




DECREASES COMPLICATIONS

Subcutaneous emphysema ^{9,10}
Ileus rates ^{11,12}
Warm ischemia time ¹³
Blood pressure ^{6,7,8}




POST-OP METRICS

8 published studies showed that
operating at low pressure with AirSeal
yielded a reduction in postoperative
pain scores and up to: ^{1-3, 8, 14-17}



REDUCTION IN HOSPITAL
LENGTH OF STAY



REDUCTION IN PACU
LENGTH OF STAY



*Based on a 2023 market analysis

This material provides information regarding how to use CONMED medical devices and instruments in surgical procedures. It is not medical advice, and each surgeon should use their own professional judgment before using to treat a particular patient. Surgeons should be trained in the use of such devices before surgery and should always refer to the product labeling including the Instructions for Use before using any medical device.

1. Ramshaw B, Forman B, Heidel E, Dean J, Gamenthaler A, Fabian M. A Clinical Quality Improvement (CQI) Project to Improve Pain After Laparoscopic Ventral Hernia Repair. *Surg Technol Int*. 2016;29:125-130.
2. Foley CE, Ryan E, Huang JQ. Less is more: clinical impact of decreasing pneumoperitoneum pressures during robotic surgery. *J Robot Surg*. 2021;15(2):299-307. doi:10.1007/s11701-020-01104-4c
3. Saway JP, McCaul M, Mulekar MS, McMahon DP, Richards WO. Review of Outcomes of Low Verses Standard Pressure Pneumoperitoneum in Laparoscopic Surgery. *Am Surg*. 2022;88(8):1832-1837. doi:10.1177/00031348221084956
4. Bucur P, Hofmann M, Menhadji A, et al. Comparison of Pneumoperitoneum Stability Between a Valveless Trocar System and Conventional Insufflation: A Prospective Randomized Trial. *Urology*. 2016;94:274-280. doi:10.1016/j.urology.2016.04.022
5. Covotta M, Claroni C, Torregiani G, et al. A Prospective, Randomized, Clinical Trial on the Effects of a Valveless Trocar on Respiratory Mechanics During Robotic Radical Cystectomy: A Pilot Study. *Anesth Analg*. 2017;124(6):1794-1801. doi:10.1213/ANE.0000000000002027
6. Abaza R, Ferroni MC. Randomized Trial of Ultralow vs Standard Pneumoperitoneum during Robotic Prostatectomy. *J Urol*. 2022;208(3):626-632. doi:10.1097/JU.0000000000002729
7. Sroussi J, Elies A, Rigouzzo A, et al. Low pressure gynecological laparoscopy (7mmHg) with AirSeal® System versus a standard insufflation (15mmHg): A pilot study in 60 patients. *J Gynecol Obstet Hum Reprod*. 2017;46(2):155-158. doi:10.1016/j.jogoh.2016.09.003
8. Buda A, Di Martino G, Borghese M, et al. Low-Pressure Laparoscopy Using the AirSeal System versus Standard Insufflation in Early-Stage Endometrial Cancer: A Multicenter, Retrospective Study (ARIEL Study). *Healthcare (Basel)*. 2022;10(3):531. Published 2022 Mar 14. doi:10.3390/healthcare10030531
9. Feng TS, Heulitt G, Islam A, Porter JR. Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial. *J Robot Surg*. 2021;15(3):381-388.
10. Desroches B, Porter J, Bhayani S, Figenshau R, Liu PY, Stifelman M. Comparison of the Safety and Efficacy of Valveless and Standard Insufflation During Robotic Partial Nephrectomy: A Prospective, Randomized, Multi-institutional Trial. *Urology*. 2021;153:185-191. doi:10.1016/j.urology.2021.01.047 doi:10.1007/s11701-020-01117-z
11. Rohloff M, Cicic A, Christensen C, Maatman TK, Lindberg J, Maatman TJ. Reduction in postoperative ileus rates utilizing lower pressure pneumoperitoneum in robotic-assisted radical prostatectomy. *J Robot Surg*. 2019;13(5):671-674. doi:10.1007/s11701-018-00915-w
12. Grieco M, Tirelli F, Agnes A, Santocchi P, Biondi A, Persiani R. High-pressure CO2 insufflation is a risk factor for postoperative ileus in patients undergoing TaTME. *Updates Surg*. 2021;73(6):2181-2187. doi:10.1007/s13304-021-01043-1
13. Annino F, Topazio L, Autieri D, Verdacchi T, De Angelis M, Asimakopoulos AD. Robotic partial nephrectomy performed with Airseal versus a standard CO2 pressure pneumoperitoneum insufflator: a prospective comparative study. *Surg Endosc*. 2017;31(4):1583-1590. doi:10.1007/s00464-016-5144-y
14. Ferroni MC, Abaza R. Feasibility of robot-assisted prostatectomy performed at ultra-low pneumoperitoneum pressure of 6 mmHg and comparison of clinical outcomes vs standard pressure of 15 mmHg. *BJU Int*. 2019;124(2):308-313. doi:10.1111/bju.14682
15. Ramshaw B, Vetrano V, Jagadish M, Forman B, Heidel E, Mancini M. Laparoscopic approach for the treatment of chronic groin pain after inguinal hernia repair : Laparoscopic approach for inguinodynia. *Surg Endosc*. 2017;31(12):5267-5274. doi:10.1007/s00464-017-5600-3
16. Abaza R, Martinez O, Ferroni MC, Bsatee A, Gerhard RS. Same Day Discharge after Robotic Radical Prostatectomy. *J Urol*. 2019;202(5):959-963. doi:10.1097/JU.0000000000000353
17. Celarier S, Monziols S, Célrier B, et al. Low-pressure versus standard pressure laparoscopic colorectal surgery (PAROS trial): a phase III randomized controlled trial. *Br J Surg*. 2021;108(8):998-1005. doi:10.1093/bjs/zna069